CureVac N.V. (FRA:5CV)

CureVac Statistics

Total Valuation

CureVac has a market cap or net worth of EUR 1.01 billion. The enterprise value is 622.69 million.

Market Cap	1.01B
Enterprise Value	622.69M

Important Dates

The last earnings date was Wednesday, November 12, 2025.

Earnings Date	Nov 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	225.18M
Shares Outstanding	n/a
Shares Change (YoY)	-38.70%
Shares Change (QoQ)	-21.60%
Owned by Insiders (%)	5.56%
Owned by Institutions (%)	22.26%
Float	125.88M

Valuation Ratios

The trailing PE ratio is 7.82.

PE Ratio	7.82
Forward PE	n/a
PS Ratio	14.24
PB Ratio	1.16
P/TBV Ratio	1.19
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 3.10, with an EV/FCF ratio of -5.02.

EV / Earnings	4.83
EV / Sales	8.72
EV / EBITDA	3.10
EV / EBIT	3.39
EV / FCF	-5.02

Financial Position

The company has a current ratio of 3.70, with a Debt / Equity ratio of 0.04.

Current Ratio	3.70
Quick Ratio	1.88
Debt / Equity	0.04
Debt / EBITDA	0.18
Debt / FCF	-0.28
Interest Coverage	29.46

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	20.18%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	983
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, CureVac has paid 28.57 million in taxes.

Income Tax	28.57M
Effective Tax Rate	18.15%

Stock Price Statistics

The stock price has increased by +59.65% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+59.65%
50-Day Moving Average	4.56
200-Day Moving Average	4.03
Relative Strength Index (RSI)	37.51
Average Volume (20 Days)	17,138

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.18

Income Statement

In the last 12 months, CureVac had revenue of EUR 70.74 million and earned 128.82 million in profits. Earnings per share was 0.80.

Revenue	70.74M
Gross Profit	65.99M
Operating Income	182.08M
Pretax Income	157.40M
Net Income	128.82M
EBITDA	193.69M
EBIT	182.08M
Earnings Per Share (EPS)	0.80

Balance Sheet

The company has 416.09 million in cash and 35.07 million in debt, giving a net cash position of 381.02 million.

Cash & Cash Equivalents	416.09M
Total Debt	35.07M
Net Cash	381.02M
Net Cash Per Share	n/a
Equity (Book Value)	871.23M
Book Value Per Share	4.81
Working Capital	636.94M

Cash Flow

In the last 12 months, operating cash flow was -120.14 million and capital expenditures -3.99 million, giving a free cash flow of -124.13 million.

Operating Cash Flow	-120.14M
Capital Expenditures	-3.99M
Free Cash Flow	-124.13M
FCF Per Share	n/a

Margins

Gross margin is 93.29%, with operating and profit margins of 257.38% and 182.11%.

Gross Margin	93.29%
Operating Margin	257.38%
Pretax Margin	222.50%
Profit Margin	182.11%
EBITDA Margin	273.81%
EBIT Margin	257.38%
FCF Margin	n/a

Dividends & Yields

CureVac does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	38.70%
Shareholder Yield	38.70%
Earnings Yield	12.79%
FCF Yield	-12.32%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CureVac has an Altman Z-Score of 1.52 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.52
Piotroski F-Score	2